LVTX — LAVA Therapeutics NV Income Statement
0.000.00%
Last trade - 00:00
- $71.77m
- -$17.49m
- $6.77m
- 34
- 14
- 86
- 41
R2019 December 31st | R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 3.5 | 5 | 19.4 | 6.77 |
Cost of Revenue | |||||
Gross Profit | — | — | — | — | 3.29 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 9.58 | 18.4 | 49.4 | 54.2 | 50 |
Operating Profit | -9.58 | -14.9 | -44.4 | -34.8 | -43.3 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -9.69 | -15.5 | -45.2 | -31.7 | -41.7 |
Provision for Income Taxes | |||||
Net Income After Taxes | -9.69 | -15.5 | -45.3 | -31.9 | -42 |
Net Income Before Extraordinary Items | |||||
Net Income | -9.69 | -15.5 | -45.3 | -31.9 | -42 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -9.69 | -15.5 | -45.3 | -31.9 | -42 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.382 | -0.612 | -2.3 | -1.23 | -1.57 |